Debiopharm reaches key development milestones for Staphylococcus-selective antibiotic Debio 1450
Debiopharm International has announced various significant achievements in the development of its new antibiotic Debio 1450, selectively active on staphylococcal species including hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA).
